Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7)

AIMS: The aim of this study was to describe the risks of cardiovascular (CV) events and severe hypoglycaemia with insulin degludec (degludec) vs insulin glargine 100 units/mL (glargine U100) in patients with type 2 diabetes (T2D) aged 65 years or older. MATERIALS AND METHODS: A total of 7637 patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Pratley, Richard E., Emerson, Scott S., Franek, Edward, Gilbert, Matthew P., Marso, Steven P., McGuire, Darren K., Pieber, Thomas R., Zinman, Bernard, Hansen, Charlotte T., Hansen, Melissa V., Mark, Thomas, Moses, Alan C., Buse, John B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617815/
https://www.ncbi.nlm.nih.gov/pubmed/30850995
http://dx.doi.org/10.1111/dom.13699

Ejemplares similares

Ejemplares similares